CardioSert is developing a novel Crossing Guide Wire for revascularization of chronic total occluded (CTO) coronary and peripheral arteries.The Crossing Guide Wire has unique features such as: Producing elevated tapping impact on the calcified lesion for ultimate CTO penetration. Steering and redirecting by changing the length and the curvature of the wire’s tip during the operation. Modifying the flexibility and stiffness during the operation without replacing the wire. Allows the usage of commonly used coronary balloons (OTW and monorail).
Coeruleus is a pharmaceutical company, under Meytag Incubator, Katzrin, Israel. The company was founded March 2009 and within 2 years of activities has achieved a novel line of formulations, strong IP, performed pre-clinical and clinical phase I/IIA human study and approached the FDA for the 5052B fast track.
Coeruleus' therapeutic approach is based on a proprietary sublingual spray formulation incorporating the active ingredient Flumazenil, a generic drug indicated to counteract GABAA related sedatives, currently administered only via intravenous (IV) injection. The company touches several unmet needs including the sleep market, drug abuse, alcohol intoxication and more. All are related to the GABAA.
Flometrica develops personal and accurate disposable urine analyzers which provide diagnostics of urine parameters ranging from urine flow to urine chemistry and biology. Flometrica’s analyzers are designed to be used by patients, anywhere, without any professional assistance. Once the analysis has been completed the patient disposes of the analyzer kit and the result is easily provided to the patient’s doctor.
Founded in 2007, Fulcrum is a biopharmaceutical company developing a drug carrier delivery platform for therapeutic drugs based on the SP-1 protein class. Fulcrum’s platform is based on nano-bio materials, which permit it to target pathology-linked conditions such as cancer, osteoarthritis and Alzheimer. The company has an irrevocable, exclusive, and unlimited worldwide license from the Hebrew University to research, develop and apply the SP-1 protein. The company completed feasibility studies in mice and has begun efficiency tests in animals and intends to conduct an additional series of animal tests to further examine and demonstrate the efficiency and reduced toxicity of SP-1 compounded antineoplastics. Fulcrum has been granted patents on its core technology’s composition of matter and method of production.
InMotion Medical Ltd., a development-stage Israeli medical device company, plans to commercialize a disposable, self-navigating colonoscopic device based on the Company’s patented technology. Colonoscopies employing conventional, semi-rigid colonoscopes can be painful, so most patients are moderately or deeply-sedated. Sedating patients, the need to disinfect colonoscopes between use and the substantial physical effort and expertise required of physicians to navigate the colonoscope through the colon present difficulties for healthcare providers, who are pursuing a disposable self navigating device.
Founded in October 2008, LunGuard is a device based company engaged in developing a novel Peristaltic Feeding Tube (PFT) catering to hospitalized patients in Intensive Care Units (ICU). The purpose of the PFT is two fold: to act as an improved lumen feeding tube, in addition to being a preventive measure to Ventilator Associated Pneumonia (VAP). VAP is the leading cause of morbidity and mortality in intensive care units (ICU’s) and LunGuard’s innovative PFT device may significantly reduce the incidences of VAP, translating into shorter hospitalization periods, better ICU medical care and reduced mortality cases. LunGuard, backed by the Maayan Venture Technology Incubator, successfully established its proof-of-concept in animal trials and should start first in man trials in November 2010.LunGuard has submitted a PCT application.
MicroSert Ltd. is developing an intraocular implant for the treatment of chronic eye diseases such as AMD and DME. AMD and DME, both leading causes of blindness, are treated with monthly intravitreal injections (insertion of a needle into the eye) of Lucentis or Avastin. Extremely non patient-friendly, involves safety issues and delivers a peak drug concentration. MicroSert’s implant is a micro capsule replacing these intravitreal injections. It is a reservoir type device inserted into the eye through a fine needle via a simple procedure, releasing Lucentis/Avastin in a sustained controlled manner, for a long period of time, and refilled for continued use. MicroSert's implant is essentially unique from existing technologies: No chemical drug-device interaction – releasing off-the-shelf drugs, empty-phase insertion – miniature cross section (surgical incision not necessary), refillable and simple insertion procedure.
The company is developing prenatal screening for chromosomal defects by a simple maternal blood test. Using MPT’s proprietary Foetal-MpsSep TM column, the foetal MPs are isolated from the mother’s blood and subjected to analysis. MPT’s product will be clinically validated for trisomy 21 and will be expanded to trisomy 18 and 13 as well as other foetal chromosome abnormalities.
The company demonstrated the first proof of concept of the technology while taking a specific disease such as the “Down Syndrome” defect and compares the results against the amniotic fluid test. Within two years the company will have a full blood test kit which could replace the amniotic fluid test in several specific genetic diseases.
Founded in November 2009, Paindure is developing a biodegradable implant-based product enabling minimally invasive localized targeted therapy for treating migraine headaches. Treatment involves administering a long-term (6 month) local anesthetic. Prototype development can be completed within a 12-18 month period. Patents – provisionally submitted on March 2009 regarding new use drug combination, new combination of formulation (slow release) and new administration.
Founded in 2008, RapiDx is a device based company developing a next-generation self-use rapid blood diagnostic test for the growing OTC homecare market. RapTest, is designed with an automated technique/platform to extract blood from the fingertip in a less painful manner, while maintaining a blood-free environment. The company has completed developing its first working prototype and is in its final stages of developing the first generation RapTest product. Two patent applications were submitted on the integration concept, one for the mechanism and design of the device (at the national stage) and one regarding the blood extraction and pain reduction via the RapTest’s automated blood extraction technique.
Founded in 2008, SeamVad is a product based biotechnology company whose breakthrough device enables a qualitatively new approach to vascular anastomosis (surgical connecting / joining between two blood vessels such as in bypass surgery). The company completed the SeamVad Connector’s proof-of-concept in an animal study and is in the midst of developing a fully automatic device (adaptor + connector). The company submitted a US patent application for the connector and the method and intends to submit additional patent applications during the development process.